Livio Trusolino

Navedeno

	Vse	Od leta 2020
Navedbe	23301	11223
indeks h	70	50
indeks i10	120	97

2300

1150

575

1725

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202578 80 146 184 199 227 234 246 262 266 408 442 569 673 884 1020 1205 1437 1396 1741 1935 2270 2269 2197 2173 370

Javni dostop

Prikaži vse

86 člankov

2 članka

na voljo

ni na voljo

Na podlagi zahtev v povezavi s financiranjem

Soavtorji

Andrea BertottiUniversity of Torino - School of MedicinePreverjeni e-poštni naslov na ircc.it
francesco sassiIRCC-University of Torino School of Medicine, Laboratory of Molecular Pharmacology ItalyPreverjeni e-poštni naslov na ircc.it
Enzo MedicoProfessor of Histology, University of Torino and Head of the Laboratory of Oncogenomics, CandioloPreverjeni e-poštni naslov na ircc.it
Salvatore SienaUniversità degli Studi di Milano e Ospedale Niguarda, Milano, ItalyPreverjeni e-poštni naslov na unimi.it
Claudio IsellaIRCCPreverjeni e-poštni naslov na ircc.it
Andrea Sartore-BianchiClinical Molecular Oncology, Niguarda Cancer Center, Milano - ItalyPreverjeni e-poštni naslov na ospedaleniguarda.it
Fortunato CiardielloProfessore di oncologia medica, seconda università di napoliPreverjeni e-poštni naslov na unina2.it
Luca LazzariIFOM - FIRC Institute of Molecular OncologyPreverjeni e-poštni naslov na ifom.eu
Jos JonkersProfessor at Leiden University and group leader at Netherlands Cancer Institute, Oncode InstitutePreverjeni e-poštni naslov na nki.nl
Simona CorsoUniversity of TorinoPreverjeni e-poštni naslov na ircc.it
Charlotte RolnyAssociate professor of tumor biology, PI at Lund University and Karolinska Institutet, SwedenPreverjeni e-poštni naslov na med.lu.se
Alessandro AMOREOspedale Regina Margherita Torino, Università degli studi TorinoPreverjeni e-poštni naslov na unito.it
Massimiliano MazzoneGroup Leader, Vesalius Research CenterPreverjeni e-poštni naslov na vib-kuleuven.be
Lorenzo CapussottiChief of the Surgical Deparment- Ospedale Mauriziano "Umberto I" TorinoPreverjeni e-poštni naslov na mauriziano.it
Andrea CasazzaDirector Biology @ Montis Bioscience, BelgiumPreverjeni e-poštni naslov na montisbio.com
Guido SeriniProfessor, University of Torino School of Medicine | Candiolo Cancer Institute IRCCSPreverjeni e-poštni naslov na ircc.it
Dario RiberoDirigente Medico I livello, Divisione di Chirurgia Generale ed Oncologica, Ospedale Mauriziano Umberto IPreverjeni e-poštni naslov na mauriziano.it
Lodewyk WesselsProfessor of Computational Cancer BiologyPreverjeni e-poštni naslov na nki.nl
Giuseppe Bassoprofessor of pediatrics university paduaPreverjeni e-poštni naslov na unipd.it
Antonio PalumboUniversità di Torino; Torino ItalyPreverjeni e-poštni naslov na unito.it

Spremljaj

Livio Trusolino

Professor, University of Torino School of Medicine, Italy

Preverjeni e-poštni naslov na ircc.it - Domača stran

Targeted anti-cancer therapies animal models oncogenic signal transduction pathways


Naslov Razvrsti po navedbah Razvrsti po letniku Razvrsti po naslovu	Navedeno Navedeno	Leto
Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014	1787	2014
MET signalling: principles and functions in development, organ regeneration and cancer L Trusolino, A Bertotti, PM Comoglio Nature reviews Molecular cell biology 11 (12), 834-848, 2010	1383	2010
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019	1196	2019
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016	1055	2016
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011	1049	2011
Drug development of MET inhibitors: targeting oncogene addiction and expedience PM Comoglio, S Giordano, L Trusolino Nature reviews Drug discovery 7 (6), 504-516, 2008	984	2008
Scatter-factor and semaphorin receptors: cell signalling for invasive growth L Trusolino, PM Comoglio Nature reviews cancer 2 (4), 289-300, 2002	911	2002
Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254-268, 2017	728	2017
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013	725	2013
Stromal contribution to the colorectal cancer transcriptome C Isella, A Terrasi, SE Bellomo, C Petti, G Galatola, A Muratore, A Mellano, ... Nature genetics 47 (4), 312-319, 2015	669	2015
A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth L Trusolino, A Bertotti, PM Comoglio Cell 107 (5), 643-654, 2001	565	2001
The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015	495	2015
The Met tyrosine kinase receptor in development and cancer A Gentile, L Trusolino, PM Comoglio Cancer and metastasis reviews 27, 85-94, 2008	393	2008
Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019	389	2019
EGFR Blockade Reverts Resistance to KRAS^G12C Inhibition in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020	374	2020
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014	359	2014
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy PM Comoglio, L Trusolino, C Boccaccio Nature Reviews Cancer 18 (6), 341-358, 2018	335	2018
Interactions between growth factor receptors and adhesion molecules: breaking the rules PM Comoglio, C Boccaccio, L Trusolino Current opinion in cell biology 15 (5), 565-571, 2003	327	2003
Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. G Tripodi, F Valtorta, L Torielli, E Chieregatti, S Salardi, L Trusolino, ... The Journal of clinical investigation 97 (12), 2815-2822, 1996	322	1996
Effective drug combinations in breast, colon and pancreatic cancer cells P Jaaks, EA Coker, DJ Vis, O Edwards, EF Carpenter, SM Leto, L Dwane, ... Nature 603 (7899), 166-173, 2022	313	2022

Sistem trenutno ne more izvesti postopka. Poskusite znova pozneje.

Članki 1–20

Št. navedb na leto

Podvojene navedbe

Združene navedbe

Dodajanje soavtorjevSoavtorji

Spremljaj

Navedeno

Soavtorji